Exelixis | EXEL - Market Capitalization


Exelixis reported $14.66B in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 221M May/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
Akebia Therapeutics USD 427M 297M Dec/2025
Amgen USD 189.89B 13.64B Mar/2026
AstraZeneca USD 301.25B 13.1B Mar/2026
Bayer EUR 37.69B 1.01B May/2026
BioMarin Pharmaceutical USD 10.18B 683M May/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Cytokinetics USD 9.16B 975M May/2026
Eisai JPY 1.25T 171.13B May/2026
Eli Lilly USD 869.02B 146.97B Mar/2026
Esperion Therapeutics USD 885M 351M Dec/2025
Exelixis USD 14.34B 3.44B May/2026
Genmab DKK 20.48B 1.02B Dec/2025
Incyte USD 21.73B 3B May/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
MacroGenics USD 102M 4M Dec/2025
Merck USD 297.1B 35.84B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Nektar Therapeutics USD 15.62B 14.76B May/2026
Neurocrine Biosciences USD 15.15B 1.9B May/2026
Novartis USD 232.75B 75B May/2026
Pfizer USD 147.4B 6.42B May/2026
Takeda JPY 8.33T 681.01B May/2026
Ultragenyx Pharmaceutical USD 2.06B 1000K May/2026
Xencor USD 795M 98M May/2026